QIAGEN (NYSE:QGEN) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of QIAGEN (NYSE:QGEN) from a buy rating to a hold rating in a report issued on Saturday.

Other equities analysts also recently issued research reports about the company. UBS Group increased their price objective on QIAGEN from $48.00 to $50.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Cowen reiterated a “hold” rating on shares of QIAGEN in a research note on Thursday, August 7th. Bank of America lifted their price target on shares of QIAGEN from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Thursday, June 26th. Barclays set a $53.00 price objective on shares of QIAGEN and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of QIAGEN in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, QIAGEN has a consensus rating of “Hold” and an average target price of $49.40.

QIAGEN Stock Performance

Shares of QGEN opened at $47.30 on Friday. The company has a 50-day simple moving average of $47.05 and a two-hundred day simple moving average of $45.63. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35. The firm has a market capitalization of $10.51 billion, a PE ratio of 27.95, a price-to-earnings-growth ratio of 2.46 and a beta of 0.66. QIAGEN has a one year low of $37.63 and a one year high of $51.88.

QIAGEN (NYSE:QGEN) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.60. The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.55 EPS. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts anticipate that QIAGEN will post 2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of QIAGEN by 375.5% during the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after acquiring an additional 980 shares in the last quarter. Osaic Holdings Inc. boosted its stake in QIAGEN by 101.4% during the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock valued at $185,000 after purchasing an additional 1,951 shares during the last quarter. Orion Porfolio Solutions LLC increased its holdings in shares of QIAGEN by 120.6% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 29,361 shares of the company’s stock worth $1,411,000 after purchasing an additional 16,054 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of QIAGEN by 11.4% in the second quarter. Squarepoint Ops LLC now owns 13,548 shares of the company’s stock worth $651,000 after purchasing an additional 1,386 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its holdings in shares of QIAGEN by 57.5% during the second quarter. Neuberger Berman Group LLC now owns 30,478 shares of the company’s stock valued at $1,463,000 after purchasing an additional 11,126 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.